Investors

Press Releases

 
Press Releases
  Date Title View
Feb 10, 2011
Watertown, MA – February 10, 2011 – Tetraphase Pharmaceuticals, Inc., a clinical-stage life science company with a groundbreaking synthetic chemistry technology platform that has the power to deliver solutions to the global health crisis caused by antibiotic resistance, today announced that the Company will participate ...
Jan 24, 2011
Watertown, MA – January 24, 2011 – Tetraphase Pharmaceuticals, a clinical-stage life science company with a groundbreaking synthetic chemistry technology platform that has the power to deliver solutions to the global health crisis caused by antibiotic resistance, announced today that it has appointed Patrick Horn, M.D.,...
Nov 11, 2010
Watertown, MA – November 11, 2010 – Tetraphase Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing a portfolio of potent, novel and differentiated antibiotics designed to be effective against drug resistant bacteria, including multidrug-resistant (MDR) Gram-negative pathogens, today announced th...
Oct 12, 2010
Watertown, MA – October 12, 2010 – Tetraphase Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing a portfolio of potent, novel and differentiated antibiotics designed to be effective against drug resistant bacteria, including multidrug-resistant (MDR) ...
Oct 1, 2010
Watertown, MA – October 1, 2010 –Tetraphase Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing a portfolio of potent, novel and differentiated antibiotics designed to be effective against drug resistant bacteria, including multidrug-resistant (MDR) Gram-negative pathogens, today announced that ...
Sep 16, 2010
Watertown, MA – September 16, 2010 – Tetraphase Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing a portfolio of potent, novel and differentiated antibiotics designed to be effective against drug resistant bacteria, including multidrug-resistant (MDR) gram negative p...
Sep 15, 2010
Watertown, MA – September 15, 2010 – Tetraphase Pharmaceuticals, Inc., today presented encouraging preclinical data for its lead drug candidate, TP-434, which showed the potent antibacterial activity of TP-434 against a very broad spectrum of susceptible and multidrug-resistant pathogens. The data supported the utility ...
Sep 15, 2010
Watertown, MA –  September 15, 2010 – Tetraphase Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing a portfolio of potent, novel and differentiated antibiotics designed to be effective against drug resistant bacteria, including multidrug-resistant (MDR) gram negative ...
Sep 13, 2010
Watertown, MA – September 13, 2010 –Tetraphase Pharmaceuticals, Inc., yesterday presented new clinical and preclinical data for its lead drug candidate, TP-434, which demonstrated the novel antibiotic as a once-daily intravenous (I.V.) monotherapy capable of treating multidrug-resistant Gram-negative pathogens while als...
Sep 8, 2010
Watertown, MA – September 8, 2010 – Tetraphase Pharmaceuticals, Inc., today announced that 12 poster presentations and an oral summary presentation on preclinical and clinical data for its lead drug candidate, TP-434, will be presented at the 2010 Interscience Conference on Antimicrobial Agent...
FirstPrevious
...
14
NextLast
= add release to Briefcase